	US 12,331,315 B2
	Chimeric antigen receptor
Kevin P. Meng, Gaithersburg, MD (US); Jodi Murakami, Culver City, CA (US); Samuel T. Haile, Castro Valley, CA (US); and Edward H. Liao, Petaluma, CA (US)
Assigned to Kite Pharma, Inc., Santa Monica, CA (US)
Filed by Kite Pharma, Inc., Santa Monica, CA (US)
Filed on May 23, 2022, as Appl. No. 17/751,266.
Claims priority of provisional application 63/192,296, filed on May 24, 2021.
Prior Publication US 2023/0013874 A1, Jan. 19, 2023
Int. Cl. A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/4224 (2025.01); A61K 40/46 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); A61K 2239/38 (2023.05); A61K 2239/59 (2023.05); C07K 2317/53 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01)]

7 Claims

1. A chimeric antigen receptor (CAR), comprising:

a NKG2D ecto domain;

a transmembrane domain;

a 4-1BB costimulatory domain; and

a signaling domain consisting only of:

a CD3-epsilon signaling domain, wherein the CD3-epsilon signaling domain consisting only of an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 31.